IXEMPRA KIT

LOE Approaching

ixabepilone

NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Oct 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

semi-synthetic analog of epothilone B. Ixabepilone binds directly to β-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of αβ-II and αβ-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple…

Indications (1)

Clinical Trials (5)

NCT04796324Phase 2Terminated

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Started Mar 2021
13 enrolled
Metastatic Breast Cancer
NCT01454479Phase 1Unknown

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Started Mar 2011
24 enrolled
Recurrent Endometrial Cancer
NCT01084057Phase 1Completed

Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

Started May 2010
NCT01057212Phase 2Terminated

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Started Feb 2010
6 enrolled
Non-squamous Non-small Cell Lung Cancer
NCT01075100Phase 2Completed

Ixabepilone + Carboplatin Metastatic Breast Cancer

Started Jan 2010
103 enrolled
Metastatic Breast Cancer